Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NeuroSense Therapeutics Ltd.NRSN · Entity 7767 | Chief Executive Officer | June 16, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NeuroSense Therapeutics Ltd.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 4,534,233 |
Reported balance
After 2026-06-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-16 · Purchase · Acquired 250,000 · Balance 4,534,233 F1: On June 16, 2026, the Reporting Person acquired 250,000 ordinary shares, no par value per share, of the Issuer at a purchase price of $0.80 per share, pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 16, 2026, the Reporting Person acquired 250,000 ordinary shares, no par value per share, of the Issuer at a purchase price of $0.80 per share, pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 17, 2026 20:30 UTC | NeuroSense Therapeutics Ltd. NRSN · Entity 7767 | PurchaseOrdinary Shares | 250,000 | $0.80 | $200,000.00 |
DisclosureSEC source: 0001213900-26-069663 · ownership.xml · nonDerivative · entry 1 Ben-Noon Alon · CIK 0001901198 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,534,233 F1 · security: On June 16, 2026, the Reporting Person acquired 250,000 ordinary shares, no par value per share, of the Issuer at a purchase price of $0.80 per share, pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.